RNAi Patent Litigation Settled Among Key Players

Unlike the NFL so far, all the key players in the RNAi field got together and worked it out. 

The deal between Alnylam, Max Planck Society, UMass, and the Whitehead Institute and MIT concerns the prosecutio and disposition of the Tuschl I and Tuschl II patents.

Alnylam, UMass, and Others Settle RNAi Patent Litigation.

Max Planck will take the lead role in coordinating all prosecution of the Tuschl II family of patents worldwide.  UMass will lead prosecution of Tuschl I patents outside the US, and will sublicense TuschI II patents to Merck with permission from Alnylam.  Alnylam will receive a portion ofthe licensing fees.

Alnylam can focus on its drug programs for RSV, liver cancers, and Huntington's disease.  Max Planck will worry about the patent prosecution of TuschI II. Everyone seems happier for the experience.

 

Posted by Bruce Lehr March 15th 2011.

Comments

[Jared]

A patent is referred to a set of rights granted to an individual or business by the state that gives them public disclosure of a new invention for a specific amount of time. This grant does not actually give the holder the exclusive right to practice the invention, but simply the right to preclude other outside parties from using or imitating it. Patent Litigation is a controversy or disagreement between two independent parties regarding a dispute of intellectual or

physical property.